Doxotero-10 Injection (Doxorubicin Hydrochloride Injection BP 10 mg)

Doxotero-10 Injection is a branded oncology injectable formulation containing doxorubicin hydrochloride, a well-established anthracycline-class antineoplastic agent. Presented as a lyophilized powder for injection, Doxotero-10 Injection is designed for professional handling within regulated oncology and pharmaceutical distribution settings. AmeriDrugs supplies this product exclusively for export to licensed importers, distributors, hospitals, and pharmacies operating under prescription-based regulatory frameworks.

Active Ingredient (API + Strength)

• Active Pharmaceutical Ingredient: Doxorubicin Hydrochloride BP

• Strength: 10 mg per vial

• Dosage Form: Lyophilized powder for injection

Therapeutic Use (Informational, Non-Advisory)
Doxorubicin hydrochloride is an anthracycline antineoplastic agent utilized in approved oncology treatment protocols for a variety of solid tumors and hematological malignancies. Doxotero-10 Injection is supplied for use in accordance with locally approved clinical guidelines and regulatory authorizations. This information is provided strictly for product identification and regulatory transparency and does not constitute medical advice or therapeutic recommendations.

Dosage Form & Route of Administration

• Dosage Form: Lyophilized powder for injection

• Route of Administration: Intravenous use only

• Prescription Status: Prescription-only medicine

• Intended for professional preparation and administration within regulated healthcare environments

Quality & Manufacturing Standards
Doxotero-10 Injection is manufactured in compliance with current Good Manufacturing Practices (GMP) and applicable pharmacopeial standards. The lyophilization process ensures product stability and integrity during storage and transport. Each batch undergoes rigorous quality control testing, including sterility, potency, and physicochemical parameters, to meet international export and regulatory requirements.

Packaging Information (Export-Oriented)

• Primary Packaging: Glass vial containing lyophilized powder

• Secondary Packaging: Printed carton with regulatory-compliant labeling

• Packaging suitable for international oncology supply chains

• Export documentation and labeling support available as per destination country regulations

Target Buyers

• Licensed pharmaceutical importers and distributors

• Oncology hospitals and cancer treatment centers

• Retail and wholesale pharmacies operating under prescription regulations

• Government and private institutional procurement agencies

• International distributors specializing in oncology injectables

Regulatory & Compliance Note
Doxotero-10 Injection is a prescription-only oncology medicine intended for regulated pharmaceutical distribution. For intravenous use only. Not for direct consumer self-use. Product supply is subject to import authorization, local drug regulatory approvals, and institutional procurement policies in the destination market. AmeriDrugs follows international export compliance standards and supports required regulatory documentation.